Catalog classification, reference sizes, lab math links, and source-backed data. Educational use only — not medical advice.
Researched for: activin and myostatin signaling
Also known as: FST-315, Follistatin 315
Follistatin-315 is a shorter isoform of follistatin with reduced heparin/cell-surface-binding affinity compared to follistatin-344, which is thought to affect its tissue distribution and duration of local activity in preclinical studies of myostatin/activin-pathway inhibition. Like FS-344, it remains an investigational research compound with no FDA-approved human indication.
Catalog descriptions reflect research context only. Not a medical claim or treatment recommendation.
Data source: Protein-biology literature, black-market analytical study, and WADA rules
Reflects preclinical/research literature context only. Not a medical claim, dosing instruction, or treatment recommendation.
Reflects patterns reported in research/community literature only. Not a safety guarantee, medical advice, or interaction warning for human use.
The prior 100-200 ug SC schedule was unsupported and removed. FS315 is the mature circulating isoform; black-market products labeled 315 or 344 have documented analytical and anti-doping concerns.
Supplementary research context only. Not medical advice or a treatment recommendation.
Found a relevant Reddit or forum thread about this compound? Suggest it below. Every suggestion is reviewed by an editor before it appears -- nothing is published automatically.
Research Use Only. All content is for educational and research reference only. Not medical advice, a treatment recommendation, or guidance on human use. Compounds are not FDA-approved drugs unless specifically noted.